Method for treating multi-drug resistant tumors
    11.
    发明授权
    Method for treating multi-drug resistant tumors 有权
    多药耐药肿瘤治疗方法

    公开(公告)号:US07303760B2

    公开(公告)日:2007-12-04

    申请号:US10714085

    申请日:2003-11-14

    摘要: Methods for administering mitomycin C to a multi-drug resistant cell and for reducing the toxicity of the compound are described. In the methods, mitoymic C is provided in the form of a prodrug conjugate, where the drug is linked to a hydrophobic moiety, such as a lipid, through a cleavable dithiobenzyl linkage. The dithiobenzyl linkage is susceptible to cleavage by mild thiolysis, resulting in release of mitomycin C in its original form. The linkage is stable under nonreducing conditions. The prodrug conjugate can be incorporated into liposomes for administration in vivo and release of mitomycin C in response to endogenous in vivo reducing conditions or in response to administration of an exogenous reducing agent.

    摘要翻译: 描述了向多药耐药细胞施用丝裂霉素C并降低化合物的毒性的方法。 在该方法中,丝裂蛋白C以前体药物缀合物的形式提供,其中药物通过可裂解的二硫代苄基键连接到疏水部分,例如脂质。 二硫代苄基键易受到轻度硫解的裂解,导致丝裂霉素C以其原始形式释放。 在非还原条件下,连接是稳定的。 可以将前体药物缀合物掺入用于体内施用的体内脂质体中,并响应内源性体内还原条件或响应外源性还原剂的施用而释放丝裂霉素C.

    Liposome formulations of boronic acid compounds
    15.
    发明申请
    Liposome formulations of boronic acid compounds 审中-公开
    硼酸化合物的脂质体制剂

    公开(公告)号:US20060159736A1

    公开(公告)日:2006-07-20

    申请号:US11267076

    申请日:2005-11-04

    摘要: A liposome composition comprised of liposomes having the peptide boronic acid proteasome inhibitor compound bortezomib entrapped in the liposomes is described. The boronic acid compound is entrapped in the liposomes in the form of a boronate ester, subsequent to interaction with a liposome-entrapped polyol. In one embodiment, the liposomes have an outer coating of hydrophilic polymer chains and are used to treat a solid tumor in a subject.

    摘要翻译: 描述了脂质体组合物,其包含被脂质体包埋的具有肽硼酸蛋白酶体抑制剂化合物硼替佐米的脂质体。 在与脂质体包被的多元醇相互作用后,硼酸化合物以硼酸酯的形式包埋在脂质体中。 在一个实施方案中,脂质体具有亲水性聚合物链的外涂层,并且用于治疗受试者中的实体瘤。

    BINDING PARTNERS WITH IMMUNOGLOBULIN DOMAINS MODIFIED TO HAVE EXTENDED HALF-LIFE
    19.
    发明申请
    BINDING PARTNERS WITH IMMUNOGLOBULIN DOMAINS MODIFIED TO HAVE EXTENDED HALF-LIFE 审中-公开
    与免疫球蛋白域的绑定合作伙伴修饰为延长生命的寿命

    公开(公告)号:US20090306349A1

    公开(公告)日:2009-12-10

    申请号:US12295334

    申请日:2007-03-30

    IPC分类号: C07K16/00 C07K1/107

    摘要: A method for conjugation of glycosylated Fc-containing proteins is described. The method comprises carbamate chemistry performed and neutral pH or below and the resulting Fc-containing protein are expected to retain tertiary structure and therefore Fc-related bioactivity such as FcR binding, the ability to bind Clq, in addition to retaining ligand binding capabilities related to the incorporation of a ligand binding peptide or other polypeptide which has binding specificity. The method is exemplified using an erythropoietin-mimetic peptide fused to a human IgG1 antibody constant domain comprising a hinge, CH2 and CH3.

    摘要翻译: 描述了用于缀合含糖基化Fc的蛋白质的方法。 该方法包括进行的氨基甲酸酯化学和中性pH或以下,并且预期所得的含Fc蛋白质可保留三级结构,因此除了保持与之相关的配体结合能力之外,还可以将Fc相关生物活性例如FcR结合,Clq结合能力 掺入具有结合特异性的配体结合肽或其他多肽。 该方法使用与包含铰链,CH2和CH3的人IgG1抗体恒定结构域融合的促红细胞生成素模拟肽来举例说明。